<DOC>
	<DOCNO>NCT01693549</DOCNO>
	<brief_summary>The purpose study determine whether cabazitaxel effective treatment metastatic breast cancer .</brief_summary>
	<brief_title>Study Cabazitaxel Patients With Metastatic Breast Cancer Previously Treated With Taxanes</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Written inform consent Female patient age 18 75 year Patients must receive 1stline chemotherapy locally recurrent / metastatic disease Prior taxanecontaining treatment ( paclitaxel , docetaxel nabpaclitaxel ) , either advanced disease neoadjuvant/adjuvant chemotherapy . In case early relapse ( relapse neoadjuvant/adjuvant chemotherapy diseasefree interval le 6 month ) , neoadjuvant/adjuvant chemotherapy consider 1stline treatment Diagnosis HER2 negative ( HER2 &lt; 2+ immunohistochemistry and/or FISH CISH negative ) metastatic breast adenocarcinoma confirm pathology department enrol institution Eastern Cooperative Oncology Group performance status ( PS ) 01 Life expectancy least 12 week Measurable disease Response Criteria Solid Tumors 1.1 ( RECIST 1.1 ) method ( least one measurable lesion ) Laboratory value within specify range within 1 week study enrolment : 1 . Hemoglobin ≥ 9.0 g/dL 2 . Absolute neutrophil count ≥ 1.5 x 10^9/L 3 . Thrombocyte count ≥ 100 x 10^9/L 4 . Serum creatinine ≤ 1.5 upper limit normal ( ULN ) . If creatinine 1.0 1.5 x ULN , creatinine clearance calculate accord CKDEPI formula patient creatinine clearance &lt; 60 mL/min exclude 5 . SGOT ( AST ) , SGPT ( ALT ) ≤ 2.5 x ULN alkaline phosphatase ≤ 2.5 x ULN , total bilirubin ≤ ULN ( limit also refer patient liver metastasis ) Previous treatment locoregional disease allow , include surgical procedure palliative radiotherapy ( treatment must complete least 4 week enrolment ) Compliance patient regard schedule visit , treatment plan , laboratory test procedure study . The enrolment patient control brain metastasis allow ( metastasis treat radiotherapy remain stable least 4 week follow completion radiation treatment ) Patients receive one line chemotherapy locally recurrent/metastatic disease Concurrent plan treatment strong inhibitor strong inducer cytochrome P450 3A4/5 ( washout period two week necessary patient already treatment ) Patients CTC grade 2 great neuropathy baseline Diagnosis spinal cord compression carcinomatous meningitis Uncontrolled severe illness medical condition ( include uncontrolled diabetes mellitus ) Patients clinically significant cardiac disease ( e.g . congestive heart failure , unstable angina , myocardial infarction ) within 6 month study entry Any significant acute chronic medical psychiatric condition abnormal laboratory finding , accord investigator 's opinion , could result excessive danger , regard participation patient study . Psychiatric disorder condition render subject incapable complying requirement protocol Any concurrent active malignancy nonmelanoma skin cancer situ carcinoma cervix Concurrent administration investigational treatment and/or antineoplastic agent Pregnancy lactation . Patients surgically sterile postmenopausal must agree use adequate contraceptive method study period . For patient childbearing potential serum urine pregnancy test need . The definition effective contraceptive method base investigator 's opinion . History severe hypersensitivity reaction ( ≥grade 3 ) docetaxel polysorbate 80 containing drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HER-2 negative</keyword>
	<keyword>Metastatic breast adenocarcinoma</keyword>
</DOC>